Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC002 in CLDN18.2-positive advanced solid tumors
NCT05472857Phase 1Recruiting
- Sponsor
- Immunofoco
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of claudin 18.2 CAR-T in gastric cancer (GC), pancreatic cancer (PC), ovarian carcinoma and 1 more, sponsored by Immunofoco. Primary endpoints: Incidence of Treatment Related Adverse Events at 12 months and Maximum Tolerated Dose at 28 days. Started Aug 2022; status: recruiting.
02
Drugs
claudin 18.2 CAR-T
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)ovarian carcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05472857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472857.